How to Learn Biostatistics

Learn the core framework of statistical inference: sampling distributions, the Central Limit Theorem, confidence intervals, hypothesis testing, p-values, Type I and Type II errors, and statistical power. Practice with one-sample and two-sample t-tests, chi-square tests, and paired tests.

Understand the key study designs in biomedical research: cross-sectional, case-control, cohort, and randomized controlled trials. Learn about bias, confounding, effect modification, measures of association (relative risk, odds ratio), and how study design influences the strength of causal inference.

Master regression methods central to biostatistical analysis. Start with simple and multiple linear regression for continuous outcomes, then move to logistic regression for binary outcomes. Learn to interpret coefficients, assess model fit, check assumptions, and handle confounders through multivariable adjustment.

Learn methods for analyzing time-to-event data, including the Kaplan-Meier estimator, the log-rank test, and the Cox proportional hazards model. Understand censoring, hazard functions, the proportional hazards assumption, and how to interpret hazard ratios in clinical research contexts.

Develop hands-on proficiency with at least one major statistical software environment. R is the most widely used in academic biostatistics; SAS is standard in the pharmaceutical industry; Python (with scipy, statsmodels, lifelines) is increasingly popular. Practice reading data, performing analyses, and creating publication-quality visualizations.

Explore methods for repeated-measures and longitudinal data, including generalized estimating equations (GEE) and mixed-effects models. Gain an introduction to Bayesian statistics, including prior specification, posterior inference, Markov chain Monte Carlo, and applications in clinical trials and genomics.

Study the design, conduct, and analysis of clinical trials in depth. Learn about Phase I-IV trial design, sample size estimation, interim analyses, adaptive designs, data safety monitoring boards, intention-to-treat versus per-protocol analysis, and the regulatory requirements of agencies like the FDA and EMA.